GlassScriptPhysician profile
Courtney Arn
NPI 1669996815
$195,168.72
in general payments reported to CMS, 2019-2025
10 companies · $37K in 2025
The $37K reported for 2025 was more than what 99% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37K · 2022: $35K · 2023: $30K · 2024: $56K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Travel and Lodging: $38K · Consulting Fee: $19K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,118 · Food and Beverage: $6,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,870.81 |
| Travel and Lodging | $37,802.13 |
| Consulting Fee | $19,329.64 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,117.50 |
| Food and Beverage | $6,183.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $64,613.85 | 2021-2025 | Tivdak, Epkinly |
| Eisai INC. | $46,446.10 | 2021-2025 | |
| Abbvie INC. | $24,423.06 | 2024-2025 | |
| Pfizer INC. | $16,178.60 | 2024-2025 | |
| Seagen INC. | $13,747.45 | 2021-2022 | |
| Immunogen, INC. | $11,477.53 | 2023 | Elahere |
| Astrazeneca Pharmaceuticals LP | $9,151.02 | 2021-2024 | Enhertu |
| Glaxosmithkline, LLC. | $5,013.03 | 2023-2024 | Jemperli, Zejula |
| Corcept Therapeutics | $2,318.08 | 2025 | |
| Roche Diagnostics Corporation | $1,800.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Arn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.